Drug Trial Radar · NCT07538570
Evaluation of Pain Treatment After Total Knee Arthroplasty
Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
66
Actual
Start
Apr 24, 2026
Primary completion
Oct 12, 2026
Study completion Oct 22, 2026
Sponsor
- Lead sponsor
- Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
- Sponsor type
- Industry
- First posted
- Apr 20, 2026
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to characterize opioid use after total knee arthroplasty (TKA).
Conditions
- Pain
Interventions
SuzetrigineDrug
Tablets for oral administration.
PlaceboDrug
Placebo matched to SUZ for oral administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Total Opioid UsageTime frame: 24 hours to 168 hours after the first dose of study drug
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Legent Orthopedic and Spine Hospital
Bellaire, Texas
Memorial Hermann Village Office
Houston, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.